Results 131 to 140 of about 8,661 (182)

A SARS-CoV-2 M^pro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibility. [PDF]

Nat Commun
Min SC, Seo JJ, Jeong JH, Kim BK, Park JH, Lee JR, Lee DG, Lee GC, An SH, Baek YH, Choi YK, Choo H, Park HY, Kim G, Jeon B, Shin SC, Song MS.   +16 more
europepmc   +1 more source

Regioselective multicomponent synthesis of α-boryl ureas: discovery of a potent main protease inhibitor. [PDF]

Org Biomol Chem
Gyasi YI, Nyalata S, Pa S, Gunasekera D, Vulupala VR, Mallampudi NR, Ramidi GR, Xu S.   +7 more
europepmc   +1 more source

Impact of Single Halogen Atom Substitutions on Antiviral Profile of Inhibitors Targeting SARS-CoV‑2 Main Protease. [PDF]

ACS Omega
Bulut H, Higashi-Kuwata N, Ogata-Aoki H, Hayashi H, Takamune N, Kishimoto N, Das D, Li M, Wlodawer A, Misumi S, Tamamura H, Mitsuya H.   +11 more
europepmc   +1 more source

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source

Persistent SARS-CoV-2 Infection in an Immunocompromised Host Treated Successfully With the Japanese Herbal Medicine, Mao-to: A Case Report. [PDF]

Am J Case Rep
Yamada T, Sonoda S, Otsuka M, Shirai T, Tateishi T, Furusawa H, Miyazaki Y.   +6 more
europepmc   +1 more source

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative. [PDF]

Open Forum Infect Dis
Essam Nkodo EN, Maheria P, Hurwitz E, Anzalone AJ, Li D, Islam JY, Sun J, Varley CD, Butzin-Dozier Z, Safo SE, Kirksey K, Hassan SA, Camacho-Rivera M, Patel RC, Fadul N.   +14 more
europepmc   +1 more source

Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023. [PDF]

Antimicrob Steward Healthc Epidemiol
Hohenstein L, Maloney M, Banach DB.
europepmc   +1 more source

A split luciferase system for studying coronavirus M^pro dimerization in vitro and in living cells. [PDF]

J Biol Chem
Delgado R, Vishwakarma J, Sanlley Hernandez JO, Tansiongco M, Cuell A, Dabrowska A, Basu R, Schmidpeter PAM, Hu Y, Tsutakawa SE, Cooley CB, Amaro RE, Harris RS.   +12 more
europepmc   +1 more source

SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots. [PDF]

Emerg Microbes Infect
Zhou Y, Gammeltoft KA, Tjørnelund-Sjursen HD, Ryberg LA, Offersgaard A, Czarnota A, Duan Z, Pham LV, Fahnøe U, Peters GHJ, Ramirez S, Bukh J, Gottwein JM.   +12 more
europepmc   +1 more source

Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease. [PDF]

Viruses
Maryam A, Moquin SA, Dovala D, Kaur J, Kurt Yilmaz N, Shaqra AM, Schiffer CA.   +6 more
europepmc   +1 more source